Added to YB: 2026-05-12
Pitch date: 2026-05-10
JBIO [neutral]
Jade Biosciences, Inc.
-6.05%
current return
Author Info
No bio for this author
Company Info
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Market Cap
$1.3B
Pitch Price
$26.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.22
P/E
-12.22
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - Jade Biosciences, Inc.
JBIO (earnings): Q1 loss $40.4M on R&D buildout. $311M cash, runway to H1 2028. JADE101 anti-APRIL Phase 1 data at ERA Congress, Phase 2 IgAN starts Q2 2026 w/ interim 2027. JADE201 anti-BAFF-R Phase 1 RA Q2 2026, interim 2027. JADE301 first-in-human H1 2027. 3 INDs in flight, clean autoimmune platform.
Read full article (1 min)